Eight drugmakers -- including Novartis AG and Teva Pharmaceutical Industries -- obtained FDA approval to market copies of Depakote DR, a delayed-release treatment for epilepsy, bipolar disorder and migraines from Abbott Laboratories. The generic treatments will have the same safety label as the brand-name version, including a "black box" warning about the risk of death from liver injury or pancreas inflammation.

Full Story:

Related Summaries